[Cell Reports] Researchers demonstrated that genetic loss of protein kinase Cι alters the trajectory of mouse Kras/Trp53-driven lung adenocarcinoma tumors from one resembling lung development to one mimicking lung regeneration.
[Science Signaling] The authors found that inhibiting the proximal receptor tyrosine kinase signaling intermediate SOS1 promoted continued osimertinib efficacy in sensitive cells and restored sensitivity in cells with acquired resistance.
[Cancer Gene Therapy] Investigators reconstructed the epithelial-to-mesenchymal transition (EMT) spectrum in lung adenocarcinoma by integrating single-cell RNA sequencing data with advanced cell trajectory inference techniques.
[Cell Biology International] The authors summarize and compare previous studies of the application and complementarity of organ-chip technologies and traditional animal models for investigating the same genetic alterations.
[Broad Institute] The US FDA has approved sevabertinib, which was developed by Bayer Healthcare Pharmaceuticals in close collaboration with the Broad, and is the first FDA-approved medicine from the long-standing Broad-Bayer oncology research alliance.
[Nature Communications] Researchers showed that the chromatin accessibility profiles of myelodysplastic syndrome stem cells more accurately reflect disease status than those of progenitor cells and reveal the process of stem cell alterations during disease progression.
[Cell Death & Disease] The authors discuss current evidence suggesting that the acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) system can be targeted for the prevention or treatment of a wide range of liver diseases.
[Nature Communications] Researchers found that NIMA-related kinase 7 (NEK7), targeted to mitochondria by its signal peptides, binds to succinate dehydrogenase complex iron sulfur subunit B (SDHB), stabilizing the spatial conformation of complex II and promoting forward electron transport.